Healthcare provider profile · identity verified

Rebekah Fu, MD

Internal Medicine · ALBUQUERQUE, NM · NPI 1710071188

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	931	304
Losartan Potassium	Losartan Potassium	696	220
Amlodipine Besylate	Amlodipine Besylate	423	144
Alendronate Sodium	Alendronate Sodium	306	96
Levothyroxine Sodium	Levothyroxine Sodium	302	82
Metformin Hcl	Metformin Hcl	205	82
Metoprolol Succinate	Metoprolol Succinate	160	56
Fluticasone Propionate	Fluticasone Propionate	147	75
Furosemide	Furosemide	139	51
Rosuvastatin Calcium	Rosuvastatin Calcium	128	42
Omeprazole	Omeprazole	127	47
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	123	36
Simvastatin	Simvastatin	117	43
Albuterol Sulfate Hfa	Albuterol Sulfate	113	42
Pantoprazole Sodium	Pantoprazole Sodium	105	36
Lisinopril	Lisinopril	104	38
Eliquis	Apixaban	100	27
Famotidine	Famotidine	98	44
Hydrochlorothiazide	Hydrochlorothiazide	92	30
Tamsulosin Hcl	Tamsulosin Hcl	88	32
Escitalopram Oxalate	Escitalopram Oxalate	83	29
Jardiance	Empagliflozin	78	27
Allopurinol	Allopurinol	75	30
Gabapentin	Gabapentin	74	25
Glipizide Er	Glipizide	74	24
Potassium Chloride	Potassium Chloride	74	30
Ozempic	Semaglutide	69	22
Carvedilol	Carvedilol	68	23
Prednisone	Prednisone	63	44
Azithromycin	Azithromycin	59	51
Donepezil Hcl	Donepezil Hcl	59	18
Olmesartan Medoxomil	Olmesartan Medoxomil	59	17
Finasteride	Finasteride	56	17
Pravastatin Sodium	Pravastatin Sodium	56	21
Trazodone Hcl	Trazodone Hcl	55	24
Tramadol Hcl	Tramadol Hcl	54	21
Zolpidem Tartrate	Zolpidem Tartrate	54	19
Atenolol	Atenolol	48	14
Irbesartan	Irbesartan	48	14
Clopidogrel	Clopidogrel Bisulfate	46	15
Lovastatin	Lovastatin	41	11
Montelukast Sodium	Montelukast Sodium	41	16
Synthroid	Levothyroxine Sodium	39	suppressed
Nifedipine Er	Nifedipine	38	12
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	37	11
Glimepiride	Glimepiride	37	13
Breo Ellipta	Fluticasone/Vilanterol	36	13
Ezetimibe	Ezetimibe	36	12
Meclizine Hcl	Meclizine Hcl	36	19
Januvia	Sitagliptin Phosphate	35	13
Candesartan Cilexetil	Candesartan Cilexetil	32	suppressed
Benazepril Hcl	Benazepril Hcl	31	suppressed
Metformin Hcl Er	Metformin Hcl	31	11
Metoprolol Tartrate	Metoprolol Tartrate	31	12
Glipizide	Glipizide	30	12
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	30	suppressed
Valacyclovir	Valacyclovir Hcl	30	12
Hydralazine Hcl	Hydralazine Hcl	29	suppressed
Raloxifene Hcl	Raloxifene Hcl	29	suppressed
Alprazolam	Alprazolam	28	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	28	suppressed
Mirtazapine	Mirtazapine	28	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	28	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	28	12
Gemfibrozil	Gemfibrozil	27	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	26	22
Risedronate Sodium	Risedronate Sodium	26	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	25	suppressed
Ketoconazole	Ketoconazole	25	16
Ipratropium Bromide	Ipratropium Bromide	24	suppressed
Mounjaro	Tirzepatide	24	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	23	19
Prolia	Denosumab	22	12
Felodipine Er	Felodipine	21	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	21	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	21	12
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	20	suppressed
Levofloxacin	Levofloxacin	20	17
Myrbetriq	Mirabegron	20	suppressed
Oxycodone Hcl	Oxycodone Hcl	20	13
Incruse Ellipta	Umeclidinium Bromide	19	suppressed
Lorazepam	Lorazepam	19	suppressed
Telmisartan	Telmisartan	19	suppressed
Vascepa	Icosapent Ethyl	19	suppressed
Betamethasone Dipropionate	Betamethasone Dipropionate	18	12
Celecoxib	Celecoxib	18	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	18	suppressed
Mupirocin	Mupirocin	17	12
Solifenacin Succinate	Solifenacin Succinate	17	suppressed
Clonazepam	Clonazepam	16	suppressed
Enalapril Maleate	Enalapril Maleate	16	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	16	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	16	suppressed
Baclofen	Baclofen	15	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	15	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	15	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	15	suppressed
Sertraline Hcl	Sertraline Hcl	15	suppressed
Valsartan	Valsartan	15	suppressed
Brilinta	Ticagrelor	14	suppressed
Buspirone Hcl	Buspirone Hcl	14	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	14	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	13	suppressed
Chlorthalidone	Chlorthalidone	13	suppressed
Colchicine	Colchicine	13	suppressed
Fingolimod	Fingolimod Hcl	13	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	13	13
Ramipril	Ramipril	13	suppressed
Cephalexin	Cephalexin	12	suppressed
Citalopram Hbr	Citalopram Hydrobromide	12	suppressed
Dropsafe Prep Pads	Alcohol Antiseptic Pads	12	suppressed
Duloxetine Hcl	Duloxetine Hcl	12	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	12	suppressed
Labetalol Hcl	Labetalol Hcl	12	suppressed
Novolog Mix 70-30 Flexpen	Insulin Aspart Prot/Insuln Asp	12	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Bumetanide	Bumetanide	11	suppressed
Hydrocortisone	Hydrocortisone	11	suppressed
Memantine Hcl	Memantine Hcl	11	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	11	suppressed
Ondansetron Odt	Ondansetron	11	suppressed
Phenobarbital	Phenobarbital	11	suppressed
Pregabalin	Pregabalin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error